نتایج جستجو برای: ژن brca2

تعداد نتایج: 19908  

تهرانی, محسن, ساعی راد, سمیرا, سرور, فائزه, شریف, مسعود, عابدیان کناری, سعید, غروی, محمد جواد, مریم سرور طاهر آبادیطاهر آبادی, مریم, نکوییان, رضا,

Background and purpose: Breast Cancer is one of the health problems in every population. The aim of this study was to determine the frequency of BRCA1 and BRCA2 common mutations in women whose mothers were diagnosed with breast cancer. Materials and methods: A case–control study was performed in 109 females (less than 40 years of age) who had mothers with breast cancer. For scanning of...

Journal: :gene, cell and tissue 0
fayazeh sarjooghian department of biochemistry, falavarjan branch, islamic azad university, isfahan,ir iran kahin shahanipour department of biochemistry, falavarjan branch, islamic azad university, isfahan,ir iran; department of biochemistry, falavarjan branch, islamic azad university, isfahan,ir iran ahmad shabanizadeh department of anatomy, rafsanjan university of medical sciences, rafsanjan,ir iran

background ovarian cancer is the most common fatal gynecologic malignancy in women. the brca2 gene has a role in regulation of cell cycle during proliferation, differentiation and dna repair. changes in the methylation of brca2 may be an effective mechanism for ovarian cancer. objectives the aim of the present study was to evaluate the association between ovarian cancer and methylation status o...

Journal: :Cancer research 2014
Muthana Al Abo Donniphat Dejsuphong Kouji Hirota Yasukazu Yonetani Mitsuyoshi Yamazoe Hitoshi Kurumizaka Shunichi Takeda

BRCA1, BRCA2, and PALB2 are key players in cellular tolerance to chemotherapeutic agents, including camptothecin, cisplatin, and PARP inhibitor. The N-terminal segment of BRCA2 interacts with PALB2, thus contributing to the formation of the BRCA1-PALB2-BRCA2 complex. To understand the role played by BRCA2 in this complex, we deleted its N-terminal segment and generated BRCA2(Δ)(N) mutant cells....

2009
Asta Björk Jonsdottir Maaike P. G. Vreeswijk Ron Wolterbeek Peter Devilee Hans J. Tanke Jorunn E. Eyfjörd Karoly Szuhai

BACKGROUND Inherited mutations in the tumour suppressor gene BRCA2 greatly increase the risk of developing breast, ovarian and other types of cancers. So far, most studies have focused on the role of BRCA-pathways in the maintenance of genomic stability. In this study we investigated the potential role of the BRCA2 protein in cytokinesis in unmodified primary human fibroblast carrying a heteroz...

Journal: :Journal of the National Cancer Institute 2002
Jeffrey L Hilton John P Geisler Jennifer A Rathe Melanie A Hattermann-Zogg Barry DeYoung Richard E Buller

BACKGROUND Although BRCA1 and BRCA2 play important roles in hereditary ovarian cancers, the extent of their role in sporadic ovarian cancers and their mechanisms of inactivation are not yet well understood. Our goal was to characterize BRCA2 mutations and mRNA expression in a group of ovarian tumors previously evaluated for BRCA1 mutations and mRNA expression. METHODS The tumors of 92 unrelat...

2016
Xia Ding Arnab Ray Chaudhuri Elsa Callen Yan Pang Kajal Biswas Kimberly D Klarmann Betty K Martin Sandra Burkett Linda Cleveland Stacey Stauffer Teresa Sullivan Aashish Dewan Hanna Marks Anthony T Tubbs Nancy Wong Eugen Buehler Keiko Akagi Scott E Martin Jonathan R Keller André Nussenzweig Shyam K Sharan

Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib has been approved for treatment of advanced ovarian cancer associated with BRCA1 and BRCA2 mutations. BRCA1- and BRCA2-mutated cells, which are homologous recombination (HR) deficient, are hypersensitive to PARPi through the mechanism of synthetic lethality. Here we examine the effect of PARPi on HR-proficient cells. Olaparib pretre...

Journal: :Cancer research 2009
Wataru Sakai Elizabeth M Swisher Céline Jacquemont Kurapaty Venkatapoorna Chandramohan Fergus J Couch Simon P Langdon Kaitlyn Wurz Jake Higgins Emily Villegas Toshiyasu Taniguchi

Acquired platinum resistance is a serious problem in the treatment of ovarian carcinomas. However, the mechanism of the drug resistance has not been elucidated. Here, we show functional significance of restoration of BRCA2 protein by secondary BRCA2 mutations in acquired drug resistance of BRCA2-mutated ovarian carcinoma. Three ovarian cancer cell lines (PEO1, PEO4, and PEO6) were derived from ...

ژورنال: پژوهش در پزشکی 2004
Ann Dalton, , David p. Hornby, , وحید رضا یاسایی, ,

Background: Breast cancer is the most common female malignancy and the main cause of death in  mid-aged women. Genetic germ line mutations in BRCAI/BRCA2 in Iranian women with breast or  ovarian cancer have not been yet reported. Materials and methods: Clinical data, family history and blood samples were obtained from 83  females aged less than 45 years with primary breast cancer in order to su...

Journal: :Cancer detection and prevention 2006
Ritva Karhu Eeva Laurila Anne Kallioniemi Kirsi Syrjäkoski

BACKGROUND Germ-line mutations of the BRCA2 gene are the highest known risk factors for male breast cancer (MBC). Mutations in BRCA2 are mainly point mutations in contrast to BRCA1 in which large genomic rearrangements are quite common. In recent literature, however, genomic alterations of BRCA2 have been linked especially to male breast cancer families. We wanted to screen large genomic deleti...

Journal: :Cancer research 2001
S C Wang K Makino L K Su A Y Pao J S Kim M C Hung

It has been suggested that BRCA2, the protein product of the breast cancer susceptibility gene BRCA2, is involved in DNA damage repair. It is therefore likely that BRCA2 plays a role in a signaling pathway induced by DNA-damaging agents. To test this possibility, we examined the alteration of the BRCA2 protein level in human cell lines after UV irradiation. We found that UV irradiation down-reg...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید